4//SEC Filing
Deschatelets Pascal 4
Accession 0001127602-24-014811
CIK 0001492422other
Filed
May 8, 8:00 PM ET
Accepted
May 9, 5:15 PM ET
Size
12.1 KB
Accession
0001127602-24-014811
Insider Transaction Report
Form 4
Deschatelets Pascal
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2024-05-08$4.31/sh+78,907$340,089→ 1,194,890 total - Sale
Common Stock
2024-05-08$42.15/sh−56,335$2,374,543→ 1,138,555 total - Sale
Common Stock
2024-05-08$42.85/sh−22,472$962,903→ 1,116,083 total - Sale
Common Stock
2024-05-08$44.02/sh−100$4,403→ 1,115,983 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-05-08−78,907→ 108,622 totalExercise: $4.31Exp: 2027-08-22→ Common Stock (78,907 underlying)
Footnotes (4)
- [F1]This is a scheduled exercise & sale from 10b5-1 trading plan dated 12/8/2023.
- [F2]This transaction was executed in multiple trades at prices ranging from $41.575 - $42.570. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F3]This transaction was executed in multiple trades at prices ranging from $42.575 - $43.545. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F4]This stock option was granted on 08/21/2017 and is fully vested.
Documents
Issuer
Apellis Pharmaceuticals, Inc.
CIK 0001492422
Entity typeother
Related Parties
1- filerCIK 0001657720
Filing Metadata
- Form type
- 4
- Filed
- May 8, 8:00 PM ET
- Accepted
- May 9, 5:15 PM ET
- Size
- 12.1 KB